Table 5. Details of the first two clinical studies of motor rehabilitation in larger cohorts in degenerative cerebellar disease [6, 7].

	Ilg et al. [6, 96]	Miyai et al. [7]
Number of patients	16	42
Type of disease	SCA6(2), SCA2(1), ADCA(1), IDCA(6), FRDA(3), SANDO(2), SN(1)	SCA6(20), ADCA(6), IDCA(16)
Age±SD (range)	61.4±11.2 (44–79)	62.5±8.0 (40–82)
Gender	8 males, 8 females	22 males, 20 females
Duration of disease	12.9±7.8 (3–25 years)	9.8±6.2(7 months–0 years)
Baseline SARA	15.8±4.3 (11–24)	11.3±3.8 (5–21.5)
Control	Intra-individual controls for short-term effect	Crossover for short-term effect
Intervention	1 h×3 per week× 4 weeks	2 h × 5 +1 h × 2 per week × 4 weeks
Post-training	Home training protocols	No
Outcome measures	SARA, gait speed, balance, BBS, GAS, movement analysis	SARA, FIM, gait speed, cadence, FAC, falls
Assessment point	4 weeks pre, baseline, post 0, 8 weeks	Baseline, post 0, 4, 12, 24 weeks
Main results	SARA and gait improved 8 weeks post-rehabilitation only in patients with cerebellar ataxia not afferent ataxia	SARA and gait improved 12 weeks but not 24 weeks

SCA spinocerebellar ataxia, FRDA Friedreich's ataxia, IDCA idiopathic cerebellar ataxia, ADCA autosomal dominant cerebellar ataxia, SANDO sensory ataxic neuropathy with dysarthria and ophthalmoparesis caused by mutations in the polymerase gamma gene, SN sensory neuropathy, SARA Scale for the Assessment and Rating of Ataxia, BBS Berg Balance score [159], GAS Goal Attainment Scaling [160], FIM Functional Independence Measure [97], FAC Functional Ambulation Categories